Viridian Therapeutics, Inc. VRDN

Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark

WALTHAM, Mass., September 02, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET.

Viridian Therapeutics (VRDN) is set to see "minimal" revenue growth in H2 before inflecting meaningf

WALTHAM, Mass., August 06, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026.

Recently published Graves Ophthalmopathy Market Insights report includes a comprehensive understanding of current treatment practices, Graves ophthalmopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now. On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc. (NASDAQ:VRDN) from $35 to $39, implying an adjusted upside potential in excess of 105% at the prevailing level. The firm maintained its Buy rating on the […]

Viridian Therapeutics (VRDN) has drawn fresh investor attention after recent trading left the stock at $19.08. Recent performance has been mixed across different periods, and the company’s business remains focused on therapies for serious and rare diseases. See our latest analysis for Viridian Therapeutics. At a share price of $19.08, Viridian Therapeutics reflects a mixed picture, with a 30 day share price return of 16.70% and a 90 day share price return of 28.23%, alongside a year to date...

Viridian Therapeutics stock has fallen 37.8% year to date, yet the valuation checks still point to the shares looking expensive rather than like a clear bargain. The year to date decline of 37.8% raises the question of whether the recent weakness has gone far enough to justify the current share price. Future revenue potential from Viridian Therapeutics' pipeline can support higher expectations, but the need to fund ongoing development and potential cash burn may weigh on what investors are...

What to make of the markets today? The biggest story in recent months has been the conflict in the Middle East and its effect on oil prices. After pulling back for a while, crude has started moving higher again as geopolitical tensions raise concerns about potential supply disruptions. Meanwhile, the Federal Reserve left interest rates unchanged at its latest meeting. Although inflation has continued to cool overall, the recent move in oil reminds investors that geopolitical developments can sti

With EPS growth for the next five years forecasted at 67.57%, Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade. On June 30, Wedbush analyst Laura Chico raised the firm’s price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $43 from $32 while maintaining an Outperform rating following […]

Viridian Therapeutics' (VRDN) Lumvoa therapy for thyroid eye disease, or TED, could start generating

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

Investing.com - U.S. stock futures rose on Monday as investors assessed reports that Washington and Tehran had agreed to halt recent hostilities around the Strait of Hormuz and resume diplomatic talks, easing fears of broader disruptions in the Middle East.

The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease.

WALTHAM, Mass., June 26, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the ey